The effect of targeted therapy on intratumoral heterogeneity has not been studied in renal cancer.
Translational relevance
The effect of targeted therapy on intratumoral heterogeneity has not been studied in renal cancer.
We report a study using a unique set of sunitinib naïve and treated clear cell renal cancer samples from patients with metastatic disease enrolled in clinical trials. There was significant intratumoral heterogeneity at protein, mRNA and DNA levels. Following sunitinib therapy there was increased intratumor heterogeneity of tumor grade, renal cancer driver gene mutations (mRNA and DNA) and protein expression. Despite this, consistent genetic alterations to key renal cancer genes occurred following sunitinib therapy. These results suggest that the commonly proposed mechanism of drug treatment enforcing clonal selection of a pre-existing clone should be reconsidered. Instead it appears that the tumor is becoming molecularly more complex, which concurs with the increased clinical difficulty in treating patients who have developed resistance to first-line targeted therapy. 
Abstract:
Purpose: The aim of this study was to investigate the effect of VEGF targeted therapy (sunitinib) on molecular intratumoral heterogeneity (ITH) in metastatic clear cell renal cancer (mccRCC).
Experimental design: Multiple tumor samples (n=187 samples) were taken from the primary renal tumors of mccRCC patients who were sunitinib treated (n=23, SuMR clinical trial) or untreated (n=23, SCOTRRCC study). ITH of pathological grade, DNA (aCGH), mRNA (Illumina Beadarray) and candidate proteins (reverse phase protein array) were evaluated using unsupervised and supervised analyses (driver mutations, hypoxia and stromal related genes). ITH was analysed using intratumoral protein variance distributions and distribution of individual patient aCGH and gene expression clustering.
Results: Tumor grade heterogeneity was greater in treated compared to untreated tumors (P=0.002). In unsupervised analysis, sunitinib therapy was not associated with increased ITH in DNA or mRNA. However, there was an increase in ITH for the driver mutation gene signature (DNA and mRNA) as well as increasing variability of protein expression with treatment (p<0.05). Despite this variability, significant chromosomal and transcript changes to key targets Introduction A number of targeted agents are available for the treatment of metastatic clear cell renal cell cancer (mccRCC), of which a VEGF tyrosine kinase inhibitor (TKI), sunitinib, is most prominent (1) . Clinical benefit with sunitinib varies between mccRCC patients, however resistance usually develops within a year in all patients. Unlike some other tumors (2) , the mechanism of TKI resistance in mccRCC is unclear.
Recent analysis of primary and metastatic RCC tissue showed significant DNA intratumoral heterogeneity (ITH), driving the hypothesis that a process of clonal evolution occurs within RCC (3, 4) . Theoretically the presence of ITH is relevant in the development of resistance to VEGF targeted therapy. It is hypothesised that one of two possible scenarios occurs in resistance to targeted therapy: (i) a single resistant clone, potentially present at baseline, predominates during resistance resulting in reduced ITH with therapy; or (ii) a multifactorial process of acquired polyclonal resistance occurs, in which there is an initial increase in ITH with the potential for development of multiple resistant clones (5).
To evaluate the effect of TKIs on ITH and provide further evidence regarding likely mechanisms of resistance to targeted therapy, multiregion tissue sampling and DNA, RNA, protein expression analysis was performed on a cohort of primary ccRCC tumors from sunitinib naïve and treated mccRCC patients to identify if: (i) molecular heterogeneity also occurred at a 6 targets and has an effect on stromal elements within the tumor (4, 6) . It is conceivable that whilst sunitinib has little effect on ITH of the whole genome it may have specific effects on drug targets and driver mutations. Also, sunitinib may have inconsistent effects on the ITH of different components of the tumor, e.g. increased ITH may be solely due to increased variability of host response to the drug in stromal elements (such as variable lymphocyte infiltration (4)), rather than direct changes to variability of tumor clones. As such, we hypothesised that sunitinib treatment results in an increase in ITH of treatment specific genes, due to treatment related pressure. Therefore, in addition to unsupervised analysis, supervised analysis was undertaken for ITH in genes associated with: (i) key driver mutations in renal cancer; (ii) stromal elements; and (iii) molecular (mainly hypoxia related) targets of sunitinib. Understanding the effect of therapy on ITH gives insight into mechanisms of drug resistance and facilitates future biomarker work and drug development.
Research. Nucleic acid/protein extraction from tissue (i) Nucleic acid DNA extraction from fresh frozen tissue was carried out using the DNeasy Blood and Tissue Kit (Qiagen, UK) according to the manufacturer's instructions. The only significant alternation to the standard protocol was the addition of a PBS washing step to remove OCT compound carried over from the process of producing cryostat sections. Samples were fragmented prior to proteinase K digestion using a Qiagen Tissue Lyser. aCGH hybridisation was carried out as described (8).
RNA extraction was carried out using miRNEasy Kit (Qiagen, UK) according the manufacturer's protocols. Amplification and analysis of the RNA was as previously described (9) .
(ii) Protein 50-75mg of tissue was placed into 2ml tubes with 990μl of lysis buffer (50mM Tris-HCl (pH 7.5), 5mM EGTA (pH 8.5), 150mM NaCl) supplemented with aprotinin (10mg/mL), phosphatase inhibitor cocktail A (Sigma, UK), phosphatase inhibitor cocktail B (Sigma, UK) and a protease inhibitor cocktail (Roche, UK). A single 5mm steel ball was added to each tube and the samples were homogenised at 50Hz twice for 5 minutes using a TissueLyser (Qiagen, UK). 10μl of Triton X-100 was added to each sample before centrifuging at 13,000g for 30 min at 4°C after which supernatants were transferred to fresh microcentrifuge tubes. Total protein concentrations were determined by BCA assay (Sigma, UK) and normalised to 1mg/mL. Array-based comparative genomic hybridisation aCGH hybridisation and analysis was carried out as recently described (8) using Roche UK Nimblegen 12X135k whole-genome array. The CGH-segMNT module of NimbleScan was used for the analysis with a minimum segment length of five probes and an averaging window of 130kb. Nimblegen arrays were positionally annotated based upon hg19 genomic coordinates and log ratio data was pre-processed in R as previously described (10) . Briefly, array data was normalised with print tip Loess from the limma package to produce normalised log ratios, filtered to remove outliers based upon a 1 MAD deviation of each probe from its immediate genomic neighbours and smoothed with a circular binary segmentation algorithm from the DNACopy package. Smoothed log ratios were then thresholded for gain/loss (±0.1) and amplification/deletion (±0.45) to identify contiguous copy number aberrations containing at least 15 consecutive probes. For clustering categorical aCGH states representing gain, loss, amplification and deletion were clustered based upon Euclidean distance using a Ward's algorithm using the segmented values from the whole genome in each case. aCGH data available via GEO (Accession number GSE67818). Gene expression analysis mRNA was amplified using the WT-Ovation FFPE System Version 2 (NuGEN, UK), purified using the Qiaquick PCR Purification Kit (Qiagen, UK), biotinylated using the Encore BiotinIL ModuleIL (NuGEN, UK), purified using minElute Reaction Cleanup Kit (Qiagen, UK) and quantified using a Bioanalyser 2100 with RNA 6000 Nano Kit (Agilent, UK). cRNA was then hybridised to Human HT-12v3 expression Beadarrays (Illumina, Cambridge, United Kingdom) according to the standard protocol for NuGEN amplified samples. Gene expression data was read and normalised with the lump package in R using variance stabilisation and robust spline normalisation. Illumina expression data was annotated based upon ensembl gene annotation (hg19, release 61). Processed data was filtered to remove probes flagged as undetected in more than 50% of the 192 samples analysed and probes with replicate gene identifiers were removed selecting those with the highest variance for each gene. For unsupervised clustering the most informative probes were selected as those with a median absolute deviation across the dataset of greater than 0.6 leaving an intrinsic dataset representing 1787 probes from unique genes. Filtered expression data was then clustered based upon Euclidean distance using a Ward's algorithm.
Gene expression data available via GEO (Accession number GSE65615).

Supervised copy number variation (CNV) and gene expression analysis
Supervised analysis was performed in order to assess clustering of individual patient tumor DNA and mRNA samples and CNV or differential gene expression with respect to molecules of relevance in renal cell cancer: (a) key molecular targets of sunitinib and hypoxia related genes; (b) stromal associated genes (extracellular matrix, stromal remodelling, and adhesion molecules) were utilised as previously described (11); and (c) a driver mutation gene set which was derived 
Reverse phase protein arrays (RPPA)
RPPA samples protein levels were determined and slides spotted as described previously (7, 12) .
Briefly, batch effects across the three slides per marker were mitigated using ComBat (13) and normalized (VSN (14)). 58 proteins making up key functional groups of proteins in RCC pathogenesis or sunitinib response were selected for study (tables S1&S2). There was no signal detected for three of the proteins (Ki67, FLT3 and phospho-Jak2), leaving 55 proteins for analysis (antibodies detailed in table S1).
Statistical analysis
As described previously, aCGH (15) and gene expression (10) cluster dendrograms were created and cut into 30 branches, those patients whose tissue samples all fell within the same branch were defined as clustered. Heterogeneity was assigned where an individual patient's samples were split between two or more clusters within the dendrogram.
Intratumoral protein variance was calculated separately for untreated and sunitinib treated patients in an ANOVA framework. Untreated and treated variance distributions combining data from all 55 proteins were compared by a Mann-Whitney test (MW). Intratumoral variances for individual proteins were compared by an F-test where assumptions of normality and homoscedasticity held, respectively assessed using the Lillefours and Fligner tests; false 
Results
Patient demographics
Of the 50 patients included in this study there was adequate tissue for analysis from 46 patients. 
Intratumoral variance in expression of candidate proteins, measured using RPPA, was marked in untreated patient samples ( fig. 2A ). But protein variance was even higher in the sunitinib treated samples compared to the untreated samples (40/55, P=0.001; fig. 2B ). Despite exacerbation of protein variance by sunitinib, there were significant differences in median expression of 30 of the 55 proteins evaluated (table S2) . There was no correlation of the effect of sunitinib on differential RNA and protein expression ( fig. S1 ). Consistent, significant changes for both mRNA and protein were only seen for 1 of the 55 proteins evaluated (Cyclin D1).
Supervised aCGH and gene expression analysis to assess ITH of relevant pathways
Three key groups of genes, relevant in renal cancer pathogenesis and TKI treatment were assessed to observe for ITH and to assess which tumor component may be driving protein ITH following sunitinib therapy. Key driver mutations, hypoxia associated genes and stroma related genes were assessed for aCGH derived CNVs (table 2 & fig. S2 ) and gene expression analysis (table 2 & fig. S2 ). Considering CNVs, there was a significant reduction in individual patient sample clustering of driver mutation (P=0.032) and hypoxia genes (P<0.001) in treated patients, suggesting increased ITH.
For gene expression analysis clustering, driver mutation genes, hypoxia and stroma associated genes had less clustering in treated samples than untreated patient samples (table 2 & fig. S2); this reduction in clustering was significant for driver mutation (p=0.006) and stroma associated genes (P=0.016) but not hypoxia genes (P=0.29).
Differential copy number variation and gene expression between untreated and treated patients
Research. Comparison of untreated and treated DNA samples revealed the significant gains or losses in the region of the following key genes ( fig. 3 ). In the treated samples there were gains of VEGFR3 and PDGFRβ and losses for VCAM1, HIF1α, CAIX, mTOR, BAP1, PBRM1, SETD2 and VHL.
Of note, no significant CNVs were seen to VEGFR2 (KDR).
Similarly, gene expression profiles of untreated and treated patient tumor RNA samples were compared (fig. 4) . Vimentin, clusterin, PDGFα, PDGFβ, VEGFA, VEGFR2 (KDR), HIF1α and CAIX all had significantly greater expression in treated tumor samples. PBRM1, KDM5C, VHL and PDGFC had significantly lower levels of expression in the treated samples. 
Discussion
Initially we showed that primary ccRCC tissue from patients treated with sunitinib expressed greater morphological heterogeneity (of tumor grade) compared to tumors from untreated patients. This was intriguing and, in view of the similar characteristics of the patient cohorts, was postulated to be treatment rather than patient related. These findings built on our previous findings from paired, sequential biopsy and nephrectomy samples which showed that sunitinib therapy was associated with increased tumor grade, lymphocyte infiltration and proliferation (Ki-67 expression) (4). This increase in pathological ITH prompted further investigation at the molecular level to determine if sunitinib treatment was associated with dynamic molecular changes resulting in a more aggressive tumor phenotype. There has been extensive work on DNA heterogeneity at a single time point, resulting in the hypothesis of specific somatic mutations, following a pattern of clonal evolution (3). In the work presented above it was hypothesised that sunitinib treatment results in an increase in ITH of treatment specific genes, due to treatment related pressure; such clonal divergence may facilitate the evolution of resistant phenotypes.
In order to test the hypothesis, we performed chromosomal, RNA and protein based analyses. Results identified ITH at every molecular level investigated, in both treated and These results allow the development of further hypotheses regarding the mechanism of acquired resistant to VEGF targeted therapy in mccRCC. The findings presented here do not support the hypothesis that a single resistant clone predominates from a number of clones after treatment commences, as treatment was associated with more rather than less ITH. As such, it can be speculated that there may be an expansion of clones, facilitating the development of resistant clones, that is polyclonal drug resistance (5). Further work using circulating samples or multiple biopsies at multiple time points throughout drug treatment would be required to prove the development of polyclonal drug resistance and allow the development of clinically relevant strategies to overcome drug resistance These findings may be relevant in optimizing the timing of immune checkpoint inhibitors in metastatic RCC. These therapies may work best in tumors with a high mutational burden (19) .
Therefore starting checkpoint inhibitor therapy after a short period of VEGF targeted therapy, when mutational burden may be higher is attractive. This approach should be considered for future clinical trials.
The final finding was that despite ITH, consistent chromosomal, RNA and protein changes to the targets of sunitinib were seen with treatment, in keeping with our previous findings regarding consistent changes in CAIX protein expression following sunitinib treatment (12) . Notable CNVs identified were losses of the renal cancer driver genes SETD2, BAP1, VHL and PBRM1 (latter two genes also had a significantly lower level of gene expression) following 
sunitinib therapy (20) . BAP1 and PBRM1 loss have previously been shown to be associated with a poor prognosis (21) . It should be noted that, together with greater levels of 3p loss in the treated patient cohort, enrichment of the 3p tumor suppressors maybe due to intrinsic differences in the unmatched patient cohorts rather than treatment; although this is thought to be unlikely due to the comparable VHL mutation rate of 78% in the untreated patients and 65% in the treated patients. Overall, these genetic alterations suggests that sunitinib is having direct effects on the tumor and further supports the hypothesis that the changes seen with sunitinib are not purely a time related phenomena.
We recognize the limitations of this study. Firstly, although the characteristics of the two groups were similar, the treated and untreated samples frozen were not matched from the same patients. However, obtaining multiple frozen samples from nephrectomy patients is challenging, requiring close interaction between urologists and pathologists (22); the multi-region sample set described here is to our knowledge the largest available. The ideal validation set of matched preand post-treatment multiregion sampled tumors is not feasible or ethical and a similar validation cohort to ours was unavailable. However, the multilevel analysis performed in this study, with all analyses confirming increasing ITH with treatment, acts as internal validation of the conclusions.
Secondly, there was a two-week break between sunitinib completion and nephrectomy, which may have influenced the results in the treated patients. Finally, sunitinib was given for a fixed period and responses to sunitinib were variable. Therefore treated samples may have been at different stages of clonal evolution. Finally, there is a justified concern that identification of study attempted to address this concern; however, this is a consideration when interpreting the data presented.
The results of this study demonstrate a more complex tumor appears to be developing following sunitinib therapy. The resulting tumor is likely to be difficult to target successfully using a 'one size fits all approach' as is currently standard of care in VEGF-targeted therapy resistant disease. These findings may in part explain why treatment in relapsed disease is particularly challenging (23) . Heatmap is a representation of all probes, created using clusters containing treatment related genes and those driving the dendrogram. Treated   SU01  3  SU04  3  SU05  3  SU06  3  SU09  3  SU11  3  SU13  3  SU16  3  SU19  3  SU22  3  SU23  3  SU25  3  SU26  3  SU32  3  SU36  3  SU39  3 Research. 
